{"gene":"FGG","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1984,"finding":"The carboxy-terminal segment of the fibrinogen gamma chain (residues γ400–411, sequence HHLGGAKQAGDV) constitutes the platelet receptor recognition site. Synthetic peptides corresponding to this region inhibit fibrinogen binding to ADP- and thrombin-stimulated platelets in a dose-dependent manner; the lysine at γ406 and the histidines at γ400–401 are required for full inhibitory activity.","method":"Synthetic peptide inhibition of 125I-fibrinogen binding to ADP/thrombin-stimulated platelets; platelet aggregation assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted binding assay with systematic peptide series and structure-activity relationship, replicated independently (Plow 1984)","pmids":["6326808","6325435"],"is_preprint":false},{"year":1984,"finding":"The γ-chain C-terminal peptide γ402–411 (GGAKQAGDV core) defines a common recognition site on activated platelets shared by fibrinogen, fibronectin, and von Willebrand factor; blocking the ε-amino group of lysine 406 abolishes inhibitory activity, demonstrating that this residue is critical for receptor recognition.","method":"Competitive inhibition of 125I-fibrinogen, 125I-fibronectin, and 125I-von Willebrand factor binding to thrombin/ADP-stimulated fixed platelets using synthetic gamma-chain peptides","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct binding competition with chemically modified peptides, orthogonally validated across three ligands","pmids":["6325435"],"is_preprint":false},{"year":1993,"finding":"Fibrinogen mediates leukocyte adhesion to vascular endothelium through a novel pathway: fibrinogen binds ICAM-1 on endothelial cells (identified by affinity chromatography and direct binding to recombinant ICAM-1) and simultaneously engages leukocyte receptors, thereby bridging leukocytes to endothelium. This pathway is independent of the classical integrin αIIbβ3 platelet receptor.","method":"Affinity chromatography purification, genetically engineered transfectants expressing ICAM-1, direct binding studies to isolated recombinant ICAM-1, cell adhesion assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — affinity purification, recombinant protein binding, transfectant validation; multiple orthogonal methods in one study","pmids":["8100742"],"is_preprint":false},{"year":1997,"finding":"Crystal structure of a 30 kDa C-terminal fragment of the fibrinogen gamma chain resolved to 2.1–2.5 Å reveals three domains including a C-terminal fibrin-polymerization domain (P) containing a single calcium-binding site and a deep binding pocket that forms the polymerization surface. The C-terminal residues (containing the factor XIIIa crosslinking site and platelet receptor recognition site) are highly flexible, and the structure has a pronounced dipole moment proposed to electrostatically steer fibrin monomer alignment.","method":"X-ray crystallography (multiple isomorphous replacement, molecular replacement); three crystal forms","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure in three independent crystal forms with functional domain assignments","pmids":["9016719"],"is_preprint":false},{"year":1997,"finding":"Crystal structure of fragment D from human fibrinogen (2.9 Å) and its crosslinked double-D counterpart from fibrin (with Gly-Pro-Arg-Pro ligand mimicking the donor polymerization site) defined the structural basis of fibrin polymerization: the coiled-coil and two homologous globular entities of the D fragment are oriented at ~130° to each other, and the Gly-Pro-Arg-Pro peptide docks into a specific pocket in the gamma-chain globular domain.","method":"X-ray crystallography; molecular replacement with GPRPam peptide ligand","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — atomic-resolution crystal structures of native fragment D and double-D fibrin crosslinked dimer with bound polymerization-site peptide","pmids":["9333233"],"is_preprint":false},{"year":2000,"finding":"The S. aureus MSCRAMM FnbpA is a bifunctional protein that binds fibrinogen in addition to fibronectin; the fibrinogen-binding activity resides in the N-terminal A region of FnbpA, which recognizes the C-terminal residues of the fibrinogen gamma chain — the same site targeted by ClfA. Surface plasmon resonance and fluorescence polarization quantified the dissociation constants for recombinant FnbpA with intact immobilized fibrinogen and with a synthetic C-terminal gamma-chain peptide.","method":"Recombinant protein expression, competitive binding assays, surface plasmon resonance, fluorescence polarization, overexpression in ClfA/ClfB-null S. aureus","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal binding methods (SPR, fluorescence polarization, competition) with recombinant proteins and defined peptide; functional validation in bacterial strain","pmids":["10788510"],"is_preprint":false},{"year":2004,"finding":"A nonsense mutation in FGG (Arg134Xaa), encoded by a split codon spanning exon 4–intron 4–exon 5, causes congenital afibrinogenemia in Lebanese patients. Expression studies in COS-7 cells showed the mutation does not affect mRNA splicing or stability but produces a severely truncated gamma chain that is unstable and not incorporated into the fibrinogen hexamer.","method":"Cell transfection (COS-7), RT-PCR (mRNA splicing/stability analysis), protein expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — functional expression studies with defined molecular outcome (truncated chain not incorporated into hexamer), multiple mechanistic endpoints","pmids":["15284111"],"is_preprint":false},{"year":2005,"finding":"A missense mutation W253C in the C-terminal globular domain of the fibrinogen gamma chain (fibrinogen Bratislava) causes hypofibrinogenemia by allowing intracellular hexamer assembly but completely blocking secretion. Co-expression of mutant FGG with wild-type FGA and FGB cDNAs in cells showed that mutant-containing hexamers assemble normally but are not secreted, demonstrating that the gamma-chain globular domain contributes to the secretion step independently of hexamer assembly.","method":"Co-expression of mutant and wild-type fibrinogen chain cDNAs in mammalian cells; ELISA of conditioned medium and cell lysates","journal":"Journal of medical genetics","confidence":"High","confidence_rationale":"Tier 2 — reconstitution co-expression system with specific mechanistic dissection of assembly vs. secretion steps","pmids":["16141000"],"is_preprint":false},{"year":2005,"finding":"The FGG-H2 haplotype (tagged by SNP 10034C/T, rs2066865) reduces DVT risk through a specific molecular mechanism: the T allele strengthens a CstF polyadenylation site, favoring production of the γA chain over the γ' chain. Reduced fibrinogen γ' levels (which contains a unique high-affinity nonsubstrate thrombin-binding site critical for antithrombin-1 activity during fibrin formation) increases thrombosis risk ~2.4-fold in homozygotes.","method":"Population-based case-control study (Leiden Thrombophilia Study) with haplotype-tagging SNPs; fibrinogen γ' quantification; multivariate analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 — genetic association with proposed molecular mechanism (CstF site); mechanistic model inferred from population data rather than direct functional assay","pmids":["16144795"],"is_preprint":false},{"year":2007,"finding":"Cancer cells (prostate DU-145, PC-3; lung A549) synthesize fibrinogen endogenously; fibrinogen augments FGF-2-stimulated cell proliferation through direct FGF-2–fibrinogen interaction. RNAi-mediated knockdown of FGG in A549 and PC-3 cells reduced fibrinogen protein production and inhibited DNA synthesis by ~60%, which was rescued by exogenous fibrinogen. FGF-2 and fibrinogen were co-immunoprecipitated from conditioned medium as a soluble complex.","method":"RNAi knockdown of FGG; [3H]-thymidine incorporation proliferation assay; co-immunoprecipitation; metabolic labeling with fluorography; FGF-2 mutant lacking fibrinogen-binding affinity","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 — RNAi knockdown with specific rescue, co-IP validation, binding-deficient FGF-2 mutant as control; multiple orthogonal methods","pmids":["17949478"],"is_preprint":false},{"year":2009,"finding":"Crystal structure of full-length human fibrinogen determined at ~3.3 Å resolution, revealing the complete hexameric (AαBβγ)2 architecture including coiled-coil regions, D and E domains. The structure adds to understanding of γ-chain domain orientation and shows prominent carbohydrate groups on β chains; αC domains lacked resolvable electron density, indicating flexibility in solution.","method":"X-ray crystallography; SDS-PAGE and N-terminal sequencing of post-diffraction crystals","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of full-length human fibrinogen with biochemical validation","pmids":["19296670"],"is_preprint":false},{"year":2010,"finding":"An FGG IVS3-2A>G splice-site mutation causes hypofibrinogenemia by generating aberrant mRNA transcripts: the major aberrant product retains intron 3, while a minor product uses a cryptic splice site in exon 4. These aberrant transcripts are predicted to be degraded before translation or to yield variant chains that undergo intracellular quality-control degradation.","method":"Minigene transfection into CHO cells; RT-PCR with agarose gel electrophoresis; nucleotide sequencing of aberrant transcripts","journal":"Clinica chimica acta","confidence":"Medium","confidence_rationale":"Tier 2 — minigene functional splicing assay with sequence-level characterization of aberrant products","pmids":["20580695"],"is_preprint":false},{"year":2013,"finding":"Nonsense-mediated mRNA decay (NMD) is the primary mechanism underlying hypofibrinogenemia caused by FGG truncating mutations. For both γ23X (frameshift, exon 3) and γ376X (nonsense, exon 9) mutations, mRNA levels were reduced compared to wild-type; cycloheximide (NMD inhibitor) dose-dependently restored mutant mRNA levels. The γ376X truncated chain was detectable in cell lysates but not in secreted fibrinogen, while γ23X chain was undetectable (fully NMD-degraded).","method":"Minigene transfection into CHO cells; real-time quantitative RT-PCR; cycloheximide NMD inhibition assay; ELISA of medium and cell lysates; immunoblot","journal":"Thrombosis research","confidence":"High","confidence_rationale":"Tier 2 — pharmacological NMD inhibition with dose-response, quantitative mRNA and protein analysis; two distinct mutations studied","pmids":["24011387"],"is_preprint":false},{"year":2016,"finding":"Compound heterozygous FGG mutations (IVS-8 deep intronic deletion and Ex-9 deletion affecting the γ' splice variant) cause hypodysfibrinogenemia through distinct mechanisms: the IVS-8 deletion produces both normal and unspliced transcripts, with unspliced products likely degraded by NMD leading to hypofibrinogenemia; the Ex-9 deletion abolishes normal γA and γ' chain production but generates an aberrant γ'409ΔA chain that is secreted more efficiently than normal fibrinogen, contributing to dysfibrinogenemia.","method":"Minigene transfection into CHO cells; RT-PCR; establishment of stable CHO cell line expressing γ'409ΔA recombinant variant; secretion assay","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 — two independent minigene constructs with functional secretion assays; mechanistically dissects two mutations","pmids":["27837696"],"is_preprint":false},{"year":2019,"finding":"FGG promotes hepatocellular carcinoma cell migration and invasion through activation of the epithelial-to-mesenchymal transition (EMT) signaling pathway, specifically by upregulating the transcription factors Slug and ZEB1. Overexpression of FGG in SK-HEP-1 cells enhanced migration and invasion, while FGG knockdown inhibited these phenotypes; EMT marker expression (E-cadherin, vimentin, Slug, ZEB1) changed concordantly.","method":"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell invasion assay; wound-healing assay; Western blot for EMT markers (Slug, ZEB1, E-cadherin, vimentin)","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 2–3 — gain- and loss-of-function with multiple functional readouts and molecular marker analysis; single lab, no mechanistic epistasis beyond EMT marker correlation","pmids":["30863175"],"is_preprint":false},{"year":2020,"finding":"FGG contributes to anthracycline (epirubicin) chemoresistance in breast cancer cells through the JAK2/STAT3 signaling pathway. Ligustrazine reversed epirubicin resistance by inhibiting JAK2/STAT3 signaling and reducing FGG expression; FGG-expressing tumor cells showed decreased response to anthracycline-based chemotherapy, and the compound eliminated cancer stem cells in resistant cells.","method":"Cell viability/drug resistance assays; JAK2/STAT3 pathway inhibition; FGG knockdown; cancer stem cell assays; clinical correlation in breast cancer tissues","journal":"American journal of cancer research","confidence":"Low","confidence_rationale":"Tier 3 — pathway placement inferred from pharmacological inhibitor without direct epistasis; limited mechanistic depth for FGG-specific mechanism","pmids":["32266101"],"is_preprint":false},{"year":2022,"finding":"A novel FGG c.8G>A mutation in the gamma-chain signal peptide causes hypofibrinogenemia associated with thrombosis. Functional analysis showed normal fibrin polymerization kinetics but reduced maximal absorbance, prolonged fibrinolysis, and structurally altered clot architecture by scanning electron microscopy. Mass spectrometry identified multiple oxidative post-translational modifications of fibrinogen in the patient, suggesting a combined effect of the signal peptide mutation and oxidative PTMs on fibrinogen function.","method":"Fibrin polymerization assay; fibrinolysis assay; scanning electron microscopy; mass spectrometry (PTM analysis); reptilase clotting assay","journal":"Blood coagulation & fibrinolysis","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays with structural imaging and MS-based PTM identification; single case/lab","pmids":["35067535"],"is_preprint":false},{"year":2022,"finding":"A 403 bp duplication of the FGG exon 8–intron 8 junction causes congenital afibrinogenemia by disrupting mRNA splicing. Because the duplication duplicates the intron 8 donor splice site, it generates multiple aberrant FGG transcripts containing premature termination codons, as demonstrated by minigene transfection analysis.","method":"Whole exome sequencing; PCR amplification and sequencing; minigene transfection into mammalian cells; mRNA splicing analysis","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 — minigene functional assay confirms splice disruption mechanism; novel large rearrangement characterized","pmids":["34196169"],"is_preprint":false},{"year":2024,"finding":"A novel heterozygous missense mutation FGG c.1168G>T impairs fibrinogen synthesis, secretion, and polymerization. Recombinant fibrinogen expression in CHO cells showed reduced protein in medium (impaired secretion) and cell lysates (impaired synthesis); thrombin-catalyzed polymerization was defective. In silico analysis indicated the mutation disrupts a hydrogen bond and impairs the 'A:a' polymerization knob-hole interaction.","method":"Recombinant CHO cell expression system; Western blotting; ELISA of medium and lysates; thrombin-catalyzed fibrin polymerization assay; in silico molecular modeling","journal":"Hereditas","confidence":"Medium","confidence_rationale":"Tier 2 — functional expression with both secretion and polymerization assays; single lab","pmids":["38233949"],"is_preprint":false},{"year":2026,"finding":"FGG promotes cholestatic liver fibrosis through two parallel mechanisms: direct activation of hepatic stellate cells (HSCs) and promotion of macrophage polarization toward the M2 phenotype. In BDL mice, FGG was upregulated and localized to activated HSCs. FGG overexpression promoted liver fibrosis in vivo; co-culture experiments showed FGG drove M2 macrophage polarization. Targeted delivery of siFGG via AEAA-modified lipid nanoparticles inhibited HSC activation and HSC–M2 macrophage crosstalk, alleviating BDL-induced fibrosis.","method":"BDL mouse model; LX2/THP-1 co-culture; FGG overexpression in vivo; siRNA knockdown via AEAA-LNP nanoparticles; RNA-seq; qRT-PCR; Western blot; immunofluorescence; macrophage polarization assays","journal":"Journal of nanobiotechnology","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function in vitro and in vivo with multiple mechanistic readouts; single lab","pmids":["42001119"],"is_preprint":false}],"current_model":"FGG encodes the fibrinogen gamma chain, whose C-terminal globular domain (structurally resolved by X-ray crystallography) contains the platelet receptor recognition site (γ400–411), a fibrin polymerization pocket, a calcium-binding site, and a factor XIIIa crosslinking site; the gamma chain mediates fibrinogen binding to platelet αIIbβ3 and ICAM-1 on endothelium, augments FGF-2-driven cell proliferation through direct complex formation, and promotes EMT-driven cancer cell invasion via Slug/ZEB1 upregulation and HSC activation/M2 macrophage polarization in fibrosis; loss-of-function mutations cause afibrinogenemia or hypofibrinogenemia through NMD of truncated transcripts, intracellular retention of misfolded hexamers, or aberrant splicing, while the γ' isoform ratio (regulated by a CstF polyadenylation site SNP) modulates thrombin's antithrombin-1 activity and DVT risk."},"narrative":{"teleology":[{"year":1984,"claim":"Identifying the minimal platelet-binding determinant on the gamma chain (γ400–411) established that a short C-terminal peptide mediates fibrinogen recognition by activated platelets and that this site is shared with fibronectin and von Willebrand factor, defining the integrin αIIbβ3 ligand-recognition paradigm.","evidence":"Synthetic peptide competition of radiolabeled fibrinogen/fibronectin/vWF binding to ADP- and thrombin-stimulated platelets with structure–activity analysis","pmids":["6326808","6325435"],"confidence":"High","gaps":["Full thermodynamic parameters for peptide–integrin interaction not determined","Three-dimensional structural basis of the γ-chain–αIIbβ3 interface unresolved at this stage"]},{"year":1993,"claim":"Demonstrating that fibrinogen binds endothelial ICAM-1 to bridge leukocytes to the vessel wall revealed an inflammation-relevant adhesion function of fibrinogen independent of its classical hemostatic integrin interactions.","evidence":"Affinity chromatography, direct binding to recombinant ICAM-1, and cell adhesion assays with ICAM-1 transfectants","pmids":["8100742"],"confidence":"High","gaps":["Gamma-chain residues responsible for ICAM-1 binding not mapped","Contribution of each fibrinogen chain to ICAM-1 recognition not dissected"]},{"year":1997,"claim":"Crystal structures of the gamma-chain C-terminal fragment and of fragment D with a bound Gly-Pro-Arg-Pro peptide provided the atomic basis for fibrin polymerization, showing a deep 'hole' pocket in the gamma domain that accepts the complementary 'knob' from adjacent fibrin monomers.","evidence":"X-ray crystallography at 2.1–2.9 Å resolution with multiple crystal forms and a synthetic polymerization-site peptide ligand","pmids":["9016719","9333233"],"confidence":"High","gaps":["Full-length hexamer structure not yet available at this point","Dynamics of polymerization pocket opening/closing not captured by static structures"]},{"year":2000,"claim":"Showing that the S. aureus adhesin FnbpA targets the same gamma-chain C-terminal site recognized by ClfA established that pathogens exploit the platelet-binding determinant of fibrinogen for host cell attachment.","evidence":"SPR, fluorescence polarization, and competitive binding assays using recombinant FnbpA domains and gamma-chain peptides in ClfA/ClfB-null S. aureus","pmids":["10788510"],"confidence":"High","gaps":["Atomic structure of FnbpA–gamma chain complex not solved","Relative in vivo contribution of FnbpA vs. ClfA to fibrinogen-dependent pathogenesis unclear"]},{"year":2005,"claim":"Functional studies of the FGG-H2 haplotype (rs2066865) linked a polyadenylation-site SNP to altered γA/γ' chain ratio and DVT risk, providing a molecular mechanism connecting fibrinogen gamma-chain isoform regulation to thrombin's antithrombin-1 activity and thrombotic disease.","evidence":"Population case-control study (Leiden Thrombophilia Study) with haplotype-tagging SNPs and fibrinogen γ' quantification","pmids":["16144795"],"confidence":"Medium","gaps":["Direct in vitro demonstration that the SNP alters CstF binding and polyadenylation not yet provided","Replication in diverse populations not reported in this study"]},{"year":2004,"claim":"Characterization of FGG loss-of-function mutations—including nonsense, missense, and splice-site variants—established that congenital afibrinogenemia and hypofibrinogenemia arise through at least three distinct pathogenic mechanisms: NMD of truncated transcripts, intracellular retention of assembled but secretion-incompetent hexamers, and aberrant mRNA splicing.","evidence":"COS-7/CHO cell transfection, co-expression of mutant and wild-type chains, cycloheximide NMD inhibition, minigene splicing assays, ELISA and immunoblot across multiple mutations","pmids":["15284111","16141000","24011387","20580695","34196169","38233949"],"confidence":"High","gaps":["Structural basis for ER retention of specific missense mutants (e.g. W253C) not determined","Genotype–phenotype correlation across mutation classes remains incomplete","NMD efficiency for different PTC positions along FGG not systematically compared"]},{"year":2007,"claim":"Demonstrating that cancer cells endogenously synthesize fibrinogen and that FGG knockdown suppresses FGF-2-dependent proliferation—rescued by exogenous fibrinogen—established a non-hemostatic, autocrine growth-promoting role for the gamma chain through direct FGF-2–fibrinogen complex formation.","evidence":"RNAi knockdown of FGG in A549/PC-3 cells; thymidine incorporation; co-immunoprecipitation of FGF-2–fibrinogen; FGF-2 binding-deficient mutant control","pmids":["17949478"],"confidence":"High","gaps":["Gamma-chain residues mediating FGF-2 binding not mapped","In vivo relevance of autocrine fibrinogen in tumor growth not demonstrated"]},{"year":2009,"claim":"The full-length human fibrinogen crystal structure at ~3.3 Å completed the atomic picture of the (AαBβγ)₂ hexamer, confirming gamma-chain domain orientation within the D region and revealing αC domain flexibility.","evidence":"X-ray crystallography of intact fibrinogen with post-diffraction biochemical validation","pmids":["19296670"],"confidence":"High","gaps":["αC domains and γ' C-terminal extension not resolved","No structure of fibrinogen in complex with platelet integrin αIIbβ3"]},{"year":2019,"claim":"Showing that FGG overexpression promotes hepatocellular carcinoma invasion via Slug/ZEB1-driven EMT extended the cancer-relevant functions of FGG beyond proliferation to invasive behavior through a specific transcription-factor axis.","evidence":"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell invasion; Western blot for EMT markers","pmids":["30863175"],"confidence":"Medium","gaps":["Upstream receptor or signaling pathway linking extracellular FGG to Slug/ZEB1 induction not identified","Findings limited to a single cell line"]},{"year":2026,"claim":"FGG was shown to drive cholestatic liver fibrosis through dual mechanisms—direct HSC activation and promotion of M2 macrophage polarization—with in vivo validation using targeted siFGG lipid nanoparticles, expanding FGG's pathological roles beyond hemostasis and cancer to fibrotic disease.","evidence":"BDL mouse model; LX2/THP-1 co-culture; FGG overexpression and siRNA knockdown in vivo via AEAA-LNP; RNA-seq and macrophage polarization assays","pmids":["42001119"],"confidence":"Medium","gaps":["Receptor on HSCs through which FGG signals is not identified","Molecular mechanism linking FGG to M2 macrophage polarization not delineated","Findings from a single lab and model system"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the gamma chain–αIIbβ3 integrin complex, the receptor and signaling pathway by which secreted FGG activates EMT and HSCs, and how oxidative post-translational modifications of fibrinogen modulate clot structure and disease risk.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal structure of gamma chain bound to integrin αIIbβ3","No receptor identified for FGG on hepatic stellate cells or cancer cells driving EMT","Functional significance of oxidative PTMs on fibrinogen gamma chain in vivo undetermined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[3,4,10]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,9]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,5,9,10]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[4,10]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,1,3,4,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[6,7,12,17]}],"complexes":["Fibrinogen hexamer (AαBβγ)₂","FGF-2–fibrinogen complex"],"partners":["FGA","FGB","ITGA2B","ITGB3","ICAM1","FGF2","F13A1"],"other_free_text":[]},"mechanistic_narrative":"FGG encodes the fibrinogen gamma chain, which assembles with the alpha and beta chains into the (AαBβγ)₂ hexamer that is the soluble precursor of fibrin and a key mediator of hemostasis, inflammation, and cell adhesion. The gamma-chain C-terminal globular domain contains the platelet integrin αIIbβ3 recognition site (γ400–411, with critical residues His400–401 and Lys406), a calcium-dependent polymerization pocket that accepts the Gly-Pro-Arg knob of fibrin monomers, and the factor XIIIa crosslinking site, as defined by peptide-inhibition studies and high-resolution crystal structures of fragment D and full-length fibrinogen [PMID:6326808, PMID:9333233, PMID:19296670]. Beyond hemostasis, fibrinogen bridges leukocytes to endothelium via ICAM-1, forms a complex with FGF-2 to augment cancer-cell proliferation, and promotes hepatic stellate cell activation and M2 macrophage polarization in liver fibrosis [PMID:8100742, PMID:17949478, PMID:42001119]. Loss-of-function FGG mutations cause congenital afibrinogenemia or hypofibrinogenemia through nonsense-mediated mRNA decay of truncated transcripts, intracellular retention of misfolded hexamers, or aberrant splicing, while the γA/γ' isoform ratio—regulated by a CstF polyadenylation-site polymorphism—modulates venous thrombosis risk [PMID:24011387, PMID:16141000, PMID:16144795]."},"prefetch_data":{"uniprot":{"accession":"P02679","full_name":"Fibrinogen gamma chain","aliases":[],"length_aa":453,"mass_kda":51.5,"function":"Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02679/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGG","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGG","total_profiled":1310},"omim":[{"mim_id":"616004","title":"DYSFIBRINOGENEMIA, CONGENITAL","url":"https://www.omim.org/entry/616004"},{"mim_id":"605776","title":"FIBRINOGEN-LIKE 1; FGL1","url":"https://www.omim.org/entry/605776"},{"mim_id":"605351","title":"FIBRINOGEN-LIKE 2; FGL2","url":"https://www.omim.org/entry/605351"},{"mim_id":"603924","title":"HYALURONAN-BINDING PROTEIN 2; HABP2","url":"https://www.omim.org/entry/603924"},{"mim_id":"603826","title":"NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 4; NR1H4","url":"https://www.omim.org/entry/603826"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":15475.1}],"url":"https://www.proteinatlas.org/search/FGG"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02679","domains":[{"cath_id":"3.90.215.10","chopping":"178-421","consensus_level":"high","plddt":96.8441,"start":178,"end":421},{"cath_id":"1.20.5","chopping":"45-95","consensus_level":"medium","plddt":80.3924,"start":45,"end":95},{"cath_id":"1.20.5","chopping":"106-156","consensus_level":"medium","plddt":94.3227,"start":106,"end":156}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02679","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02679-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02679-F1-predicted_aligned_error_v6.png","plddt_mean":85.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGG","jax_strain_url":"https://www.jax.org/strain/search?query=FGG"},"sequence":{"accession":"P02679","fasta_url":"https://rest.uniprot.org/uniprotkb/P02679.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02679/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02679"}},"corpus_meta":[{"pmid":"11354637","id":"PMC_11354637","title":"Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11354637","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32610551","id":"PMC_32610551","title":"Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32610551","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19596924","id":"PMC_19596924","title":"Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma.","date":"2009","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19596924","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30863175","id":"PMC_30863175","title":"FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30863175","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17445871","id":"PMC_17445871","title":"The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis.","date":"2007","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/17445871","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31576477","id":"PMC_31576477","title":"FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules.","date":"2019","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31576477","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15284111","id":"PMC_15284111","title":"Expression and analysis of a split premature termination codon in FGG responsible for congenital afibrinogenemia: escape from RNA surveillance mechanisms in transfected cells.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15284111","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16141000","id":"PMC_16141000","title":"Hypofibrinogenaemia caused by a novel FGG missense mutation (W253C) in the gamma chain globular domain impairing fibrinogen secretion.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16141000","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32266101","id":"PMC_32266101","title":"Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32266101","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24011387","id":"PMC_24011387","title":"Nonsense-mediated mRNA decay was demonstrated in two hypofibrinogenemias caused by heterozygous nonsense mutations of FGG, Shizuoka III and Kanazawa II.","date":"2013","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/24011387","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8428520","id":"PMC_8428520","title":"The gamma fibrinogen gene (FGG) maps to chromosome 17 in both cattle and sheep.","date":"1993","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8428520","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22836734","id":"PMC_22836734","title":"A novel regulatory element between the human FGA and FGG genes.","date":"2012","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/22836734","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26686377","id":"PMC_26686377","title":"Construction of supramolecular polymer by enzyme-triggered covalent condensation of CB[8]-FGG-based supramonomer.","date":"2016","source":"Chemical communications (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26686377","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20580695","id":"PMC_20580695","title":"In vitro transcription of compound heterozygous hypofibrinogenemia Matsumoto IX; first identification of FGB IVS6 deletion of 4 nucleotides and FGG IVS3-2A>G causing abnormal RNA splicing.","date":"2010","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20580695","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28318107","id":"PMC_28318107","title":"The amplitude of coagulation curves from thrombin time tests allows dysfibrinogenemia caused by the common mutation FGG-Arg301 to be distinguished from hypofibrinogenemia.","date":"2017","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28318107","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16959688","id":"PMC_16959688","title":"Fibrinogen Seoul (FGG Ala341Asp): a novel mutation associated with hypodysfibrinogenemia.","date":"2006","source":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/16959688","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27837696","id":"PMC_27837696","title":"Genetic analyses of novel compound heterozygous hypodysfibrinogenemia, Tsukuba I: FGG c.1129+62_65 del AATA and FGG c.1299+4 del A.","date":"2016","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/27837696","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27999448","id":"PMC_27999448","title":"Thrombosis Related ABO, F5, MTHFR, and FGG Gene Polymorphisms in Morbidly Obese Patients.","date":"2016","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/27999448","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29769041","id":"PMC_29769041","title":"Cortical atrophy and hypofibrinogenemia due to FGG and TBCD mutations in a single family: a case report.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29769041","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35067535","id":"PMC_35067535","title":"Thrombosis-associated hypofibrinogenemia: novel abnormal fibrinogen variant FGG c.8G>A with oxidative posttranslational modifications.","date":"2022","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/35067535","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31484330","id":"PMC_31484330","title":"Polymorphism rs2066865 in the Fibrinogen Gamma Chain (FGG) Gene Increases Plasma Fibrinogen Concentration and Is Associated with an Increased Microvascular Thrombosis Rate.","date":"2019","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/31484330","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38708173","id":"PMC_38708173","title":"Factor VII R353Q (rs6046), FGA A6534G (rs6050), and FGG C10034T (rs2066865) Gene Polymorphisms and Risk of Recurrent Pregnancy Loss in Iranian Women.","date":"2023","source":"Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/38708173","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37124494","id":"PMC_37124494","title":"Spatial transcriptomics reveals the heterogeneity and FGG+CRP+ inflammatory cancer-associated fibroblasts replace islets in pancreatic ductal adenocarcinoma.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37124494","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15025951","id":"PMC_15025951","title":"[Cloning and identification of fibrinogen gamma polypeptide (FGG) gene differentially expressed in human hepatocellular carcinoma].","date":"2004","source":"Ai zheng = Aizheng = Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15025951","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18615659","id":"PMC_18615659","title":"The role of weakly polar and H-bonding interactions in the stabilization of the conformers of FGG, WGG, and YGG: an aqueous phase computational study.","date":"2008","source":"Biopolymers","url":"https://pubmed.ncbi.nlm.nih.gov/18615659","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19551918","id":"PMC_19551918","title":"Recurrence of the 'deep-intronic' FGG IVS6-320A>T mutation causing quantitative fibrinogen deficiency in the Italian population of Veneto.","date":"2009","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/19551918","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38327620","id":"PMC_38327620","title":"The FGG c.952G>A variant causes congenital dysfibrinogenemia characterized by recurrent cerebral infarction: a case report.","date":"2024","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38327620","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33812435","id":"PMC_33812435","title":"[Congenital Fibrinogen Deficiency Caused by Novel FGG Gene Mutation].","date":"2021","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/33812435","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38233949","id":"PMC_38233949","title":"A novel missense mutation (FGG c.1168G > T) in the gamma chain of fibrinogen causing congenital hypodysfibrinogenemia with bleeding phenotype.","date":"2024","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/38233949","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34196169","id":"PMC_34196169","title":"A homozygous duplication of the <I>FGG</i> exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family.","date":"2022","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/34196169","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31131962","id":"PMC_31131962","title":"Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male.","date":"2019","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31131962","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38374144","id":"PMC_38374144","title":"A novel mutation in the FGG gene causes hypofibrinogenemia in a Chinese family.","date":"2024","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/38374144","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40806633","id":"PMC_40806633","title":"Genetic Associations of ITGB3, FGG, GP1BA, PECAM1, and PEAR1 Polymorphisms and the Platelet Activation Pathway with Recurrent Pregnancy Loss in the Korean Population.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40806633","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40501422","id":"PMC_40501422","title":"Hereditary hepatic fibrinogen storage disease with a novel fibrinogen variant FGG c.1113T>A ( fibrinogen Seoul III ).","date":"2025","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/40501422","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40025073","id":"PMC_40025073","title":"A familial study of a de novo FGG gene mutation causing congenital hypofibrinogenaemia and intervention during pregnancy and childbirth.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40025073","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41499360","id":"PMC_41499360","title":"Tuning the Viscoelasticity of Supramolecular Alginate Hydrogels via Homoternary FGG-Peptide-Cucurbit[8]uril Complexes.","date":"2026","source":"Biomacromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41499360","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30512152","id":"PMC_30512152","title":"[Mutation analysis of a FGG gene causing hereditary abnormal fibrinogen].","date":"2018","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30512152","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26037343","id":"PMC_26037343","title":"[Congenital hypofibrinogenemia associated with a novel mutation in FGG gene].","date":"2015","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26037343","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"42001119","id":"PMC_42001119","title":"Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis.","date":"2026","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/42001119","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33306830","id":"PMC_33306830","title":"[A case of inherited afibrinogenemia caused by an IVS7-12A>G splice mutation of FGG gene].","date":"2020","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33306830","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39473893","id":"PMC_39473893","title":"Case Report: Laboratory detection of a thrombotic tendency in a family with hypodysfibrinogenemia and a novel FGG mutation.","date":"2024","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39473893","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37906135","id":"PMC_37906135","title":"[Genetic analysis of a Chinese pedigree affected with Congenital dysfibrinogenemia due to variant of FGG gene].","date":"2023","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37906135","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41233956","id":"PMC_41233956","title":"Congenital hypofibrinogenemia with bleeding risk: mutations in the FGA, FGB, and FGG genes.","date":"2026","source":"Laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41233956","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41030265","id":"PMC_41030265","title":"Implications of the c.1201C > G (p.Arg401Gly) mutation in FGG gene on fibrinogen stability and function.","date":"2025","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41030265","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.10.16.682426","title":"Beyond the Genotype: A Multi-Omic Analysis of APOEe4’s Role in Alzheimer’s Disease","date":"2025-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.16.682426","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.05.15.654000","title":"Differential Proteomic Analysis of DEN-Induced Hepatocellular Carcinoma in Male and Female Balb/c Mice Reveals Novel Gender Specific Markers","date":"2025-05-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.15.654000","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391209","id":"PMC_10391209","title":"Characterization of single-nucleotide polymorphisms in coding regions of human genes.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391209","citation_count":1381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6383194","id":"PMC_6383194","title":"Fibrinogen and fibrin.","date":"1984","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6383194","citation_count":600,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6326808","id":"PMC_6326808","title":"Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain.","date":"1984","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6326808","citation_count":464,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17643375","id":"PMC_17643375","title":"Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17643375","citation_count":367,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9333233","id":"PMC_9333233","title":"Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9333233","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8100742","id":"PMC_8100742","title":"Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8100742","citation_count":315,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7356959","id":"PMC_7356959","title":"Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences.","date":"1980","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7356959","citation_count":294,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16581250","id":"PMC_16581250","title":"p130Cas: a versatile scaffold in signaling networks.","date":"2006","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16581250","citation_count":266,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19296670","id":"PMC_19296670","title":"Crystal structure of human fibrinogen.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19296670","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6325435","id":"PMC_6325435","title":"Evidence that three adhesive proteins interact with a common recognition site on activated platelets.","date":"1984","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6325435","citation_count":253,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6575689","id":"PMC_6575689","title":"Covalent structure of fibrinogen.","date":"1983","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/6575689","citation_count":241,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10788510","id":"PMC_10788510","title":"The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10788510","citation_count":227,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10467729","id":"PMC_10467729","title":"Fibrinogen.","date":"1999","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10467729","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23852822","id":"PMC_23852822","title":"Congenital fibrinogen disorders: an update.","date":"2013","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/23852822","citation_count":218,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9016719","id":"PMC_9016719","title":"Crystal structure of a 30 kDa C-terminal fragment from the gamma chain of human fibrinogen.","date":"1997","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/9016719","citation_count":216,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16144795","id":"PMC_16144795","title":"Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16144795","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25037231","id":"PMC_25037231","title":"Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25037231","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17949478","id":"PMC_17949478","title":"Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2).","date":"2007","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/17949478","citation_count":187,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28675934","id":"PMC_28675934","title":"Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.","date":"2017","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/28675934","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10605720","id":"PMC_10605720","title":"Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways.","date":"1999","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/10605720","citation_count":179,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24222,"output_tokens":2939,"usd":0.058375},"stage2":{"model":"claude-opus-4-6","input_tokens":6324,"output_tokens":3072,"usd":0.16263},"total_usd":0.509204,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":35828,"output_tokens":5908,"usd":0.098052},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9388,"output_tokens":3193,"usd":0.190147}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"A nonsense mutation (Arg134Xaa) in FGG, encoded by a codon split across adjacent exons (TG-intron 4-A), does not affect mRNA splicing or stability but produces an unstable, severely truncated fibrinogen gamma chain that fails to incorporate into a functional fibrinogen hexamer, demonstrating that gamma chain truncation prevents hexamer assembly.\",\n      \"method\": \"Expression of mutant FGG cDNA in COS-7 cells; mRNA stability and splicing analysis; protein assembly assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro expression with functional assembly readout, multiple orthogonal methods (mRNA analysis + protein detection)\",\n      \"pmids\": [\"15284111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The FGG missense mutation W253C (W227C in mature protein) in the C-terminal globular domain of the fibrinogen gamma chain allows intracellular hexamer assembly but prevents secretion of the assembled fibrinogen molecule, establishing that the gamma chain globular domain contains determinants required for hexamer secretion distinct from assembly.\",\n      \"method\": \"Co-expression of mutant FGG cDNA with wild-type FGA and FGB cDNAs in transfected cells; media vs. cell lysate fibrinogen detection\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution-style co-expression with secretion vs. assembly dissection, clear functional consequence\",\n      \"pmids\": [\"16141000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Nonsense mutations in FGG (γ23X and γ376X) cause hypofibrinogenemia via nonsense-mediated mRNA decay (NMD): mRNA levels from mutant alleles are reduced and increase dose-dependently upon cycloheximide (NMD inhibitor) treatment, with the γ376X truncated chain detectable in cell lysates but not assembled into intact fibrinogen.\",\n      \"method\": \"Transfection of mutant minigenes into CHO cells; real-time quantitative RT-PCR with/without cycloheximide; ELISA and immunoblot of cell lysates and media\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (NMD inhibitor rescue, quantitative mRNA, protein assay) in a single study\",\n      \"pmids\": [\"24011387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The FGG IVS3-2A>G splice-site mutation causes abnormal splicing of the FGG pre-mRNA, producing a major aberrant transcript retaining intron 3 and a minor transcript utilizing a cryptic splice site in exon 4, leading to reduced plasma fibrinogen through mRNA degradation and/or quality-control degradation of variant chains.\",\n      \"method\": \"Minigene transfection into CHO cells; RT-PCR and agarose gel electrophoresis; nucleotide sequencing of aberrant transcripts\",\n      \"journal\": \"Clinica chimica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro splicing assay with sequencing; single lab\",\n      \"pmids\": [\"20580695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A deep-intronic FGG deletion (IVS-8, c.1129+62_65 del AATA) causes aberrant splicing producing both normally spliced and unspliced products, leading to hypofibrinogenemia likely through NMD of unspliced transcripts; a second FGG deletion in exon 9 (c.1299+4 del A, Ex-9 deletion) prevents normal γA- and γ'-chain production but drives augmented production of an aberrant γ'-chain, causing hypodysfibrinogenemia. The γ'409ΔA recombinant fibrinogen was secreted more effectively than normal fibrinogen.\",\n      \"method\": \"Minigene transfection into CHO cells; RT-PCR; establishment of stable CHO cell lines producing recombinant variant fibrinogen; Western blot\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct minigene splicing assay plus recombinant protein secretion assay; single lab\",\n      \"pmids\": [\"27837696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A 403 bp duplication of the FGG exon 8–intron 8 junction duplicates the donor splice site of intron 8, causing production of multiple aberrant FGG transcripts with premature truncating codons, leading to congenital afibrinogenemia by abolishing normal gamma chain production.\",\n      \"method\": \"Whole exome sequencing; PCR and Sanger sequencing; minigene transfection into cells; mRNA analysis of aberrant transcripts\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct minigene splicing assay with mRNA characterization; single study\",\n      \"pmids\": [\"34196169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The FGG missense mutation c.1168G>T impairs recombinant fibrinogen synthesis, secretion, and thrombin-catalyzed polymerization, and in silico analysis indicates it disrupts hydrogen bonding and the 'A:a' knob-hole interaction required for fibrin polymerization.\",\n      \"method\": \"Recombinant CHO cell expression of mutant fibrinogen; Western blot and ELISA for synthesis and secretion; fibrin polymerization assay; in silico structural modeling\",\n      \"journal\": \"Hereditas\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — recombinant expression plus functional polymerization assay; single study, single lab\",\n      \"pmids\": [\"38233949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGG overexpression in HCC SK-HEP-1 cells promotes migration and invasion by activating the epithelial-to-mesenchymal transition (EMT) pathway, upregulating Slug and ZEB1; conversely, FGG knockdown inhibits migration, invasion, and EMT marker expression.\",\n      \"method\": \"Transwell and wound-healing assay; FGG overexpression and siRNA knockdown; Western blot for EMT markers (Slug, ZEB1)\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function with defined cellular phenotype and pathway markers; single lab\",\n      \"pmids\": [\"30863175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"FGG expression is elevated in activated hepatic stellate cells (HSCs) during cholestatic liver injury; FGG overexpression promotes HSC activation and drives macrophage polarization toward the M2 phenotype via HSC–macrophage crosstalk; FGG knockdown (via AEAA-lipid nanoparticle-delivered siFGG) inhibits HSC activation, disrupts M2 macrophage polarization, and alleviates liver fibrosis in a bile duct ligation mouse model.\",\n      \"method\": \"BDL mouse model; LX2 and THP-1 co-culture; FGG overexpression in mice; siRNA knockdown via targeted LNP; qRT-PCR, Western blot, RNA-seq, immunofluorescence for activation and polarization markers\",\n      \"journal\": \"Journal of nanobiotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo loss- and gain-of-function with multiple mechanistic readouts; single study\",\n      \"pmids\": [\"42001119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The FGG c.8G>A mutation in the gamma chain signal peptide results in hypofibrinogenemia with altered clot structure (lower maximal absorbance during polymerization, prolonged fibrinolysis, abnormal fibrin ultrastructure by scanning electron microscopy) and is accompanied by oxidative post-translational modifications of fibrinogen detected by mass spectrometry.\",\n      \"method\": \"Fibrin polymerization assay; fibrinolysis assay; scanning electron microscopy; mass spectrometry for PTM detection\",\n      \"journal\": \"Blood coagulation & fibrinolysis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays (polymerization, lysis, SEM, MS); single case/lab\",\n      \"pmids\": [\"35067535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The FGG missense mutation Ala341Asp (Fibrinogen Seoul) causes dysfibrinogenemia with defective thrombin-catalyzed polymerization; molecular modeling indicates a conformational change in the fibrinogen structure underlies the functional defect.\",\n      \"method\": \"Purified fibrinogen polymerization assay; molecular modeling\",\n      \"journal\": \"Clinical and applied thrombosis/hemostasis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional assay on purified protein but no mutagenesis or reconstitution; modeling only for structural inference\",\n      \"pmids\": [\"16959688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A conserved non-coding sequence (PFE2) located between the FGA and FGG genes functions as a liver-specific enhancer that potentiates FGA promoter-driven and minimal promoter-driven gene expression in hepatoma cells regardless of orientation, and drives enhanced GFP expression in transgenic zebrafish larval livers in vivo.\",\n      \"method\": \"Luciferase reporter assay in hepatoma cells; transgenic zebrafish in vivo GFP reporter assay\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo functional enhancer assays with orientation-independence control; single lab\",\n      \"pmids\": [\"22836734\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGG encodes the fibrinogen gamma chain, which assembles intracellularly with Aα and Bβ chains into a hexameric fibrinogen molecule; mutations in the gamma chain globular domain can block secretion without preventing assembly, truncating mutations cause NMD or produce chains incompatible with hexamer incorporation, splice-site mutations generate aberrant transcripts, and the assembled gamma chain contributes to thrombin-catalyzed fibrin polymerization via knob-hole interactions; beyond hemostasis, FGG promotes EMT-driven cancer cell migration/invasion and HSC activation with M2 macrophage polarization in liver fibrosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Classification notes:**\n- Papers [13] and [36] describe FGG as a peptide triplet (Phe-Gly-Gly) used in supramolecular chemistry — EXCLUDE (symbol collision, not the fibrinogen gamma gene)\n- Paper [25] from additional list is about computational conformational analysis of FGG tripeptide — EXCLUDE\n- Papers about BioPlex interactome, MGC cDNA, SNP catalogs, etc. — these are genome-wide studies that incidentally mention FGG; only include if they provide specific mechanistic findings about FGG\n- Papers [3], [6] (retrieved) — expression/prognostic studies — no mechanistic discovery\n- Papers about DVT association, SNP associations — no direct mechanism\n- Papers [1], [7], [8], [10], [14], [17], [26], [29], [30], [35] in retrieved list — contain molecular mechanism data\n- Additional paper [10] (Kloczewiak 1984), [14] (Spraggon 1997), [16] (Languino 1993), [17] (Laudano 1980), [19] (Kollman 2009), [20] (Plow 1984), [21] (Henschen 1983), [22] (Wann 2000), [24] (de Moerloose 2013), [25] (Yee 1997), [26] (Uitte de Willige 2005), [28] (Sahni 2007), [30] (Shattil 1999) — KEEP for mechanism\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"The carboxy-terminal segment of the fibrinogen gamma chain (residues γ400–411, sequence HHLGGAKQAGDV) constitutes the platelet receptor recognition site. Synthetic peptides corresponding to this region inhibit fibrinogen binding to ADP- and thrombin-stimulated platelets in a dose-dependent manner; the lysine at γ406 and the histidines at γ400–401 are required for full inhibitory activity.\",\n      \"method\": \"Synthetic peptide inhibition of 125I-fibrinogen binding to ADP/thrombin-stimulated platelets; platelet aggregation assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted binding assay with systematic peptide series and structure-activity relationship, replicated independently (Plow 1984)\",\n      \"pmids\": [\"6326808\", \"6325435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"The γ-chain C-terminal peptide γ402–411 (GGAKQAGDV core) defines a common recognition site on activated platelets shared by fibrinogen, fibronectin, and von Willebrand factor; blocking the ε-amino group of lysine 406 abolishes inhibitory activity, demonstrating that this residue is critical for receptor recognition.\",\n      \"method\": \"Competitive inhibition of 125I-fibrinogen, 125I-fibronectin, and 125I-von Willebrand factor binding to thrombin/ADP-stimulated fixed platelets using synthetic gamma-chain peptides\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding competition with chemically modified peptides, orthogonally validated across three ligands\",\n      \"pmids\": [\"6325435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Fibrinogen mediates leukocyte adhesion to vascular endothelium through a novel pathway: fibrinogen binds ICAM-1 on endothelial cells (identified by affinity chromatography and direct binding to recombinant ICAM-1) and simultaneously engages leukocyte receptors, thereby bridging leukocytes to endothelium. This pathway is independent of the classical integrin αIIbβ3 platelet receptor.\",\n      \"method\": \"Affinity chromatography purification, genetically engineered transfectants expressing ICAM-1, direct binding studies to isolated recombinant ICAM-1, cell adhesion assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — affinity purification, recombinant protein binding, transfectant validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"8100742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Crystal structure of a 30 kDa C-terminal fragment of the fibrinogen gamma chain resolved to 2.1–2.5 Å reveals three domains including a C-terminal fibrin-polymerization domain (P) containing a single calcium-binding site and a deep binding pocket that forms the polymerization surface. The C-terminal residues (containing the factor XIIIa crosslinking site and platelet receptor recognition site) are highly flexible, and the structure has a pronounced dipole moment proposed to electrostatically steer fibrin monomer alignment.\",\n      \"method\": \"X-ray crystallography (multiple isomorphous replacement, molecular replacement); three crystal forms\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure in three independent crystal forms with functional domain assignments\",\n      \"pmids\": [\"9016719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Crystal structure of fragment D from human fibrinogen (2.9 Å) and its crosslinked double-D counterpart from fibrin (with Gly-Pro-Arg-Pro ligand mimicking the donor polymerization site) defined the structural basis of fibrin polymerization: the coiled-coil and two homologous globular entities of the D fragment are oriented at ~130° to each other, and the Gly-Pro-Arg-Pro peptide docks into a specific pocket in the gamma-chain globular domain.\",\n      \"method\": \"X-ray crystallography; molecular replacement with GPRPam peptide ligand\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic-resolution crystal structures of native fragment D and double-D fibrin crosslinked dimer with bound polymerization-site peptide\",\n      \"pmids\": [\"9333233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The S. aureus MSCRAMM FnbpA is a bifunctional protein that binds fibrinogen in addition to fibronectin; the fibrinogen-binding activity resides in the N-terminal A region of FnbpA, which recognizes the C-terminal residues of the fibrinogen gamma chain — the same site targeted by ClfA. Surface plasmon resonance and fluorescence polarization quantified the dissociation constants for recombinant FnbpA with intact immobilized fibrinogen and with a synthetic C-terminal gamma-chain peptide.\",\n      \"method\": \"Recombinant protein expression, competitive binding assays, surface plasmon resonance, fluorescence polarization, overexpression in ClfA/ClfB-null S. aureus\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal binding methods (SPR, fluorescence polarization, competition) with recombinant proteins and defined peptide; functional validation in bacterial strain\",\n      \"pmids\": [\"10788510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A nonsense mutation in FGG (Arg134Xaa), encoded by a split codon spanning exon 4–intron 4–exon 5, causes congenital afibrinogenemia in Lebanese patients. Expression studies in COS-7 cells showed the mutation does not affect mRNA splicing or stability but produces a severely truncated gamma chain that is unstable and not incorporated into the fibrinogen hexamer.\",\n      \"method\": \"Cell transfection (COS-7), RT-PCR (mRNA splicing/stability analysis), protein expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional expression studies with defined molecular outcome (truncated chain not incorporated into hexamer), multiple mechanistic endpoints\",\n      \"pmids\": [\"15284111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A missense mutation W253C in the C-terminal globular domain of the fibrinogen gamma chain (fibrinogen Bratislava) causes hypofibrinogenemia by allowing intracellular hexamer assembly but completely blocking secretion. Co-expression of mutant FGG with wild-type FGA and FGB cDNAs in cells showed that mutant-containing hexamers assemble normally but are not secreted, demonstrating that the gamma-chain globular domain contributes to the secretion step independently of hexamer assembly.\",\n      \"method\": \"Co-expression of mutant and wild-type fibrinogen chain cDNAs in mammalian cells; ELISA of conditioned medium and cell lysates\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reconstitution co-expression system with specific mechanistic dissection of assembly vs. secretion steps\",\n      \"pmids\": [\"16141000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The FGG-H2 haplotype (tagged by SNP 10034C/T, rs2066865) reduces DVT risk through a specific molecular mechanism: the T allele strengthens a CstF polyadenylation site, favoring production of the γA chain over the γ' chain. Reduced fibrinogen γ' levels (which contains a unique high-affinity nonsubstrate thrombin-binding site critical for antithrombin-1 activity during fibrin formation) increases thrombosis risk ~2.4-fold in homozygotes.\",\n      \"method\": \"Population-based case-control study (Leiden Thrombophilia Study) with haplotype-tagging SNPs; fibrinogen γ' quantification; multivariate analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic association with proposed molecular mechanism (CstF site); mechanistic model inferred from population data rather than direct functional assay\",\n      \"pmids\": [\"16144795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cancer cells (prostate DU-145, PC-3; lung A549) synthesize fibrinogen endogenously; fibrinogen augments FGF-2-stimulated cell proliferation through direct FGF-2–fibrinogen interaction. RNAi-mediated knockdown of FGG in A549 and PC-3 cells reduced fibrinogen protein production and inhibited DNA synthesis by ~60%, which was rescued by exogenous fibrinogen. FGF-2 and fibrinogen were co-immunoprecipitated from conditioned medium as a soluble complex.\",\n      \"method\": \"RNAi knockdown of FGG; [3H]-thymidine incorporation proliferation assay; co-immunoprecipitation; metabolic labeling with fluorography; FGF-2 mutant lacking fibrinogen-binding affinity\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNAi knockdown with specific rescue, co-IP validation, binding-deficient FGF-2 mutant as control; multiple orthogonal methods\",\n      \"pmids\": [\"17949478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of full-length human fibrinogen determined at ~3.3 Å resolution, revealing the complete hexameric (AαBβγ)2 architecture including coiled-coil regions, D and E domains. The structure adds to understanding of γ-chain domain orientation and shows prominent carbohydrate groups on β chains; αC domains lacked resolvable electron density, indicating flexibility in solution.\",\n      \"method\": \"X-ray crystallography; SDS-PAGE and N-terminal sequencing of post-diffraction crystals\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of full-length human fibrinogen with biochemical validation\",\n      \"pmids\": [\"19296670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"An FGG IVS3-2A>G splice-site mutation causes hypofibrinogenemia by generating aberrant mRNA transcripts: the major aberrant product retains intron 3, while a minor product uses a cryptic splice site in exon 4. These aberrant transcripts are predicted to be degraded before translation or to yield variant chains that undergo intracellular quality-control degradation.\",\n      \"method\": \"Minigene transfection into CHO cells; RT-PCR with agarose gel electrophoresis; nucleotide sequencing of aberrant transcripts\",\n      \"journal\": \"Clinica chimica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — minigene functional splicing assay with sequence-level characterization of aberrant products\",\n      \"pmids\": [\"20580695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Nonsense-mediated mRNA decay (NMD) is the primary mechanism underlying hypofibrinogenemia caused by FGG truncating mutations. For both γ23X (frameshift, exon 3) and γ376X (nonsense, exon 9) mutations, mRNA levels were reduced compared to wild-type; cycloheximide (NMD inhibitor) dose-dependently restored mutant mRNA levels. The γ376X truncated chain was detectable in cell lysates but not in secreted fibrinogen, while γ23X chain was undetectable (fully NMD-degraded).\",\n      \"method\": \"Minigene transfection into CHO cells; real-time quantitative RT-PCR; cycloheximide NMD inhibition assay; ELISA of medium and cell lysates; immunoblot\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological NMD inhibition with dose-response, quantitative mRNA and protein analysis; two distinct mutations studied\",\n      \"pmids\": [\"24011387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Compound heterozygous FGG mutations (IVS-8 deep intronic deletion and Ex-9 deletion affecting the γ' splice variant) cause hypodysfibrinogenemia through distinct mechanisms: the IVS-8 deletion produces both normal and unspliced transcripts, with unspliced products likely degraded by NMD leading to hypofibrinogenemia; the Ex-9 deletion abolishes normal γA and γ' chain production but generates an aberrant γ'409ΔA chain that is secreted more efficiently than normal fibrinogen, contributing to dysfibrinogenemia.\",\n      \"method\": \"Minigene transfection into CHO cells; RT-PCR; establishment of stable CHO cell line expressing γ'409ΔA recombinant variant; secretion assay\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two independent minigene constructs with functional secretion assays; mechanistically dissects two mutations\",\n      \"pmids\": [\"27837696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGG promotes hepatocellular carcinoma cell migration and invasion through activation of the epithelial-to-mesenchymal transition (EMT) signaling pathway, specifically by upregulating the transcription factors Slug and ZEB1. Overexpression of FGG in SK-HEP-1 cells enhanced migration and invasion, while FGG knockdown inhibited these phenotypes; EMT marker expression (E-cadherin, vimentin, Slug, ZEB1) changed concordantly.\",\n      \"method\": \"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell invasion assay; wound-healing assay; Western blot for EMT markers (Slug, ZEB1, E-cadherin, vimentin)\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — gain- and loss-of-function with multiple functional readouts and molecular marker analysis; single lab, no mechanistic epistasis beyond EMT marker correlation\",\n      \"pmids\": [\"30863175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGG contributes to anthracycline (epirubicin) chemoresistance in breast cancer cells through the JAK2/STAT3 signaling pathway. Ligustrazine reversed epirubicin resistance by inhibiting JAK2/STAT3 signaling and reducing FGG expression; FGG-expressing tumor cells showed decreased response to anthracycline-based chemotherapy, and the compound eliminated cancer stem cells in resistant cells.\",\n      \"method\": \"Cell viability/drug resistance assays; JAK2/STAT3 pathway inhibition; FGG knockdown; cancer stem cell assays; clinical correlation in breast cancer tissues\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pathway placement inferred from pharmacological inhibitor without direct epistasis; limited mechanistic depth for FGG-specific mechanism\",\n      \"pmids\": [\"32266101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A novel FGG c.8G>A mutation in the gamma-chain signal peptide causes hypofibrinogenemia associated with thrombosis. Functional analysis showed normal fibrin polymerization kinetics but reduced maximal absorbance, prolonged fibrinolysis, and structurally altered clot architecture by scanning electron microscopy. Mass spectrometry identified multiple oxidative post-translational modifications of fibrinogen in the patient, suggesting a combined effect of the signal peptide mutation and oxidative PTMs on fibrinogen function.\",\n      \"method\": \"Fibrin polymerization assay; fibrinolysis assay; scanning electron microscopy; mass spectrometry (PTM analysis); reptilase clotting assay\",\n      \"journal\": \"Blood coagulation & fibrinolysis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with structural imaging and MS-based PTM identification; single case/lab\",\n      \"pmids\": [\"35067535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A 403 bp duplication of the FGG exon 8–intron 8 junction causes congenital afibrinogenemia by disrupting mRNA splicing. Because the duplication duplicates the intron 8 donor splice site, it generates multiple aberrant FGG transcripts containing premature termination codons, as demonstrated by minigene transfection analysis.\",\n      \"method\": \"Whole exome sequencing; PCR amplification and sequencing; minigene transfection into mammalian cells; mRNA splicing analysis\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — minigene functional assay confirms splice disruption mechanism; novel large rearrangement characterized\",\n      \"pmids\": [\"34196169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A novel heterozygous missense mutation FGG c.1168G>T impairs fibrinogen synthesis, secretion, and polymerization. Recombinant fibrinogen expression in CHO cells showed reduced protein in medium (impaired secretion) and cell lysates (impaired synthesis); thrombin-catalyzed polymerization was defective. In silico analysis indicated the mutation disrupts a hydrogen bond and impairs the 'A:a' polymerization knob-hole interaction.\",\n      \"method\": \"Recombinant CHO cell expression system; Western blotting; ELISA of medium and lysates; thrombin-catalyzed fibrin polymerization assay; in silico molecular modeling\",\n      \"journal\": \"Hereditas\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional expression with both secretion and polymerization assays; single lab\",\n      \"pmids\": [\"38233949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"FGG promotes cholestatic liver fibrosis through two parallel mechanisms: direct activation of hepatic stellate cells (HSCs) and promotion of macrophage polarization toward the M2 phenotype. In BDL mice, FGG was upregulated and localized to activated HSCs. FGG overexpression promoted liver fibrosis in vivo; co-culture experiments showed FGG drove M2 macrophage polarization. Targeted delivery of siFGG via AEAA-modified lipid nanoparticles inhibited HSC activation and HSC–M2 macrophage crosstalk, alleviating BDL-induced fibrosis.\",\n      \"method\": \"BDL mouse model; LX2/THP-1 co-culture; FGG overexpression in vivo; siRNA knockdown via AEAA-LNP nanoparticles; RNA-seq; qRT-PCR; Western blot; immunofluorescence; macrophage polarization assays\",\n      \"journal\": \"Journal of nanobiotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function in vitro and in vivo with multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"42001119\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGG encodes the fibrinogen gamma chain, whose C-terminal globular domain (structurally resolved by X-ray crystallography) contains the platelet receptor recognition site (γ400–411), a fibrin polymerization pocket, a calcium-binding site, and a factor XIIIa crosslinking site; the gamma chain mediates fibrinogen binding to platelet αIIbβ3 and ICAM-1 on endothelium, augments FGF-2-driven cell proliferation through direct complex formation, and promotes EMT-driven cancer cell invasion via Slug/ZEB1 upregulation and HSC activation/M2 macrophage polarization in fibrosis; loss-of-function mutations cause afibrinogenemia or hypofibrinogenemia through NMD of truncated transcripts, intracellular retention of misfolded hexamers, or aberrant splicing, while the γ' isoform ratio (regulated by a CstF polyadenylation site SNP) modulates thrombin's antithrombin-1 activity and DVT risk.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FGG encodes the fibrinogen gamma chain, which assembles with the Aα and Bβ chains into a hexameric fibrinogen molecule essential for hemostasis; the gamma chain contributes critical determinants for both intracellular hexamer secretion and thrombin-catalyzed fibrin polymerization via knob-hole interactions [PMID:16141000, PMID:38233949]. Nonsense mutations cause hypofibrinogenemia through nonsense-mediated mRNA decay or production of truncated chains that fail to incorporate into hexamers, while missense mutations in the C-terminal globular domain can permit assembly but block secretion, and splice-site mutations generate aberrant transcripts that abolish normal gamma chain production [PMID:15284111, PMID:24011387, PMID:34196169]. Mutations in FGG are causative for congenital afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia [PMID:15284111, PMID:16959688, PMID:34196169]. Beyond hemostasis, FGG promotes epithelial-to-mesenchymal transition-driven cancer cell migration via Slug and ZEB1 upregulation and drives hepatic stellate cell activation with M2 macrophage polarization in liver fibrosis [PMID:30863175, PMID:42001119].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing that severe truncation of the gamma chain prevents hexamer assembly resolved why certain nonsense mutations cause afibrinogenemia even when mRNA is stable.\",\n      \"evidence\": \"Expression of Arg134Xaa FGG cDNA in COS-7 cells with mRNA stability analysis and protein assembly assay\",\n      \"pmids\": [\"15284111\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Minimum gamma chain length required for hexamer incorporation not defined\",\n        \"Fate of unincorporated truncated chains (proteasomal vs. lysosomal degradation) not determined\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that the W253C mutation permits intracellular hexamer assembly but blocks secretion separated the gamma chain's role in secretion from its role in assembly, localizing secretion determinants to the globular domain.\",\n      \"evidence\": \"Co-expression of mutant FGG with wild-type FGA and FGB in transfected cells; media vs. lysate fibrinogen detection\",\n      \"pmids\": [\"16141000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the ER quality-control checkpoint retaining assembled but secretion-incompetent hexamers unknown\",\n        \"Whether other globular domain residues similarly dissociate assembly from secretion not tested\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Characterization of the Ala341Asp (Fibrinogen Seoul) variant linked a gamma chain globular domain substitution to defective thrombin-catalyzed polymerization, implicating this region in fibrin monomer interactions.\",\n      \"evidence\": \"Purified fibrinogen polymerization assay with molecular modeling\",\n      \"pmids\": [\"16959688\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No recombinant mutagenesis or reconstitution to confirm causality of the single substitution\",\n        \"Structural inference relies solely on modeling without experimental structural data\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating that the IVS3-2A>G splice-site mutation produces aberrant transcripts retaining intron 3 or using a cryptic splice site established that pre-mRNA splicing defects in FGG are a distinct mechanism of fibrinogen deficiency.\",\n      \"evidence\": \"Minigene transfection into CHO cells with RT-PCR and sequencing of aberrant transcripts\",\n      \"pmids\": [\"20580695\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Relative contributions of mRNA degradation vs. protein quality control to reduced fibrinogen not quantified\",\n        \"Single splice-site mutation studied; generalizability to other intronic variants not tested\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of a liver-specific enhancer (PFE2) between FGA and FGG provided a regulatory mechanism for tissue-restricted fibrinogen gene expression.\",\n      \"evidence\": \"Luciferase reporter assay in hepatoma cells; transgenic zebrafish GFP reporter in vivo\",\n      \"pmids\": [\"22836734\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether PFE2 regulates FGG transcription directly or primarily acts on FGA not resolved\",\n        \"Trans-acting factors binding PFE2 not identified\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showing that nonsense mutations γ23X and γ376X trigger NMD of FGG mRNA (rescued by cycloheximide) established NMD as a primary pathogenic mechanism in hypofibrinogenemia, complementing the earlier finding that truncated chains also fail to assemble.\",\n      \"evidence\": \"Mutant minigene transfection in CHO cells; qRT-PCR ± cycloheximide; ELISA and immunoblot\",\n      \"pmids\": [\"24011387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether residual truncated protein from NMD-escaping transcripts has dominant-negative effects unknown\",\n        \"Relative contribution of NMD vs. assembly failure in vivo not quantified\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Deep-intronic and exon 9 deletions were shown to cause aberrant splicing with distinct consequences — NMD of unspliced transcripts versus augmented production of an aberrant γ' chain with enhanced secretion — revealing that FGG splicing mutations can produce gain-of-function secretion phenotypes.\",\n      \"evidence\": \"Minigene transfection; stable CHO lines producing recombinant variant fibrinogen; Western blot\",\n      \"pmids\": [\"27837696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequences of the hyper-secreted aberrant γ' fibrinogen on clot structure and stability not assessed\",\n        \"Whether the enhanced secretion reflects altered ER quality control not explored\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that FGG overexpression activates EMT via Slug and ZEB1 upregulation to promote HCC cell migration and invasion extended FGG's functional repertoire beyond hemostasis into cancer biology.\",\n      \"evidence\": \"Transwell/wound-healing assays with FGG overexpression and siRNA knockdown in SK-HEP-1 cells; Western blot for EMT markers\",\n      \"pmids\": [\"30863175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Receptor or signaling pathway through which FGG activates EMT not identified\",\n        \"Whether secreted fibrinogen or intracellular gamma chain drives the phenotype not distinguished\",\n        \"Validation in additional HCC cell lines or in vivo models lacking\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A signal peptide mutation (c.8G>A) was shown to cause hypofibrinogenemia with altered clot ultrastructure and oxidative post-translational modifications, linking gamma chain processing defects to qualitative fibrin abnormalities.\",\n      \"evidence\": \"Fibrin polymerization and fibrinolysis assays; scanning electron microscopy; mass spectrometry for PTMs\",\n      \"pmids\": [\"35067535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal relationship between oxidative PTMs and altered clot structure not established\",\n        \"Single patient case; genotype-phenotype correlation not confirmed in independent cases\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A 403 bp duplication spanning the exon 8–intron 8 junction was shown to abolish normal gamma chain production through generation of multiple aberrant transcripts with premature stop codons, establishing large structural variants as a cause of congenital afibrinogenemia.\",\n      \"evidence\": \"WES; PCR/Sanger sequencing; minigene transfection; mRNA analysis\",\n      \"pmids\": [\"34196169\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether any aberrant transcripts escape NMD and produce dominant-negative fragments not assessed\",\n        \"Prevalence of structural variants in FGG among afibrinogenemia patients unknown\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The c.1168G>T mutation was shown to impair fibrinogen synthesis, secretion, and thrombin-catalyzed polymerization, with structural modeling indicating disruption of the A:a knob-hole interaction critical for fibrin network formation.\",\n      \"evidence\": \"Recombinant CHO cell expression; Western blot/ELISA; fibrin polymerization assay; in silico structural modeling\",\n      \"pmids\": [\"38233949\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Knob-hole disruption inferred from modeling; direct structural evidence (crystallography, cryo-EM) not obtained\",\n        \"Whether the mutation affects fibrinogen clearance in vivo not tested\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrating that FGG promotes hepatic stellate cell activation and M2 macrophage polarization via HSC–macrophage crosstalk, reversible by in vivo siRNA knockdown, established FGG as a pro-fibrotic effector in cholestatic liver injury.\",\n      \"evidence\": \"BDL mouse model; LX2/THP-1 co-culture; FGG overexpression in mice; targeted LNP-delivered siFGG; qRT-PCR, Western blot, RNA-seq, immunofluorescence\",\n      \"pmids\": [\"42001119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Receptor or signaling pathway mediating FGG-driven M2 polarization not identified\",\n        \"Whether the pro-fibrotic role is specific to the gamma chain or requires assembled fibrinogen not resolved\",\n        \"Relevance to non-cholestatic liver fibrosis models not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The receptor(s) and signaling pathways through which FGG exerts its non-hemostatic functions — EMT activation in cancer and HSC/macrophage crosstalk in fibrosis — remain unidentified, and whether these activities require secreted fibrinogen or are gamma chain-autonomous is unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No receptor identified for FGG-mediated EMT or macrophage polarization\",\n        \"Gamma chain-autonomous vs. assembled fibrinogen-dependent functions not separated\",\n        \"No structural data for disease-associated gamma chain variants beyond computational modeling\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1, 2, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 6, 9]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 1, 6, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 5, 9]}\n    ],\n    \"complexes\": [\n      \"Fibrinogen hexamer (Aα₂Bβ₂γ₂)\"\n    ],\n    \"partners\": [\n      \"FGA\",\n      \"FGB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"FGG encodes the fibrinogen gamma chain, which assembles with the alpha and beta chains into the (AαBβγ)₂ hexamer that is the soluble precursor of fibrin and a key mediator of hemostasis, inflammation, and cell adhesion. The gamma-chain C-terminal globular domain contains the platelet integrin αIIbβ3 recognition site (γ400–411, with critical residues His400–401 and Lys406), a calcium-dependent polymerization pocket that accepts the Gly-Pro-Arg knob of fibrin monomers, and the factor XIIIa crosslinking site, as defined by peptide-inhibition studies and high-resolution crystal structures of fragment D and full-length fibrinogen [PMID:6326808, PMID:9333233, PMID:19296670]. Beyond hemostasis, fibrinogen bridges leukocytes to endothelium via ICAM-1, forms a complex with FGF-2 to augment cancer-cell proliferation, and promotes hepatic stellate cell activation and M2 macrophage polarization in liver fibrosis [PMID:8100742, PMID:17949478, PMID:42001119]. Loss-of-function FGG mutations cause congenital afibrinogenemia or hypofibrinogenemia through nonsense-mediated mRNA decay of truncated transcripts, intracellular retention of misfolded hexamers, or aberrant splicing, while the γA/γ' isoform ratio—regulated by a CstF polyadenylation-site polymorphism—modulates venous thrombosis risk [PMID:24011387, PMID:16141000, PMID:16144795].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Identifying the minimal platelet-binding determinant on the gamma chain (γ400–411) established that a short C-terminal peptide mediates fibrinogen recognition by activated platelets and that this site is shared with fibronectin and von Willebrand factor, defining the integrin αIIbβ3 ligand-recognition paradigm.\",\n      \"evidence\": \"Synthetic peptide competition of radiolabeled fibrinogen/fibronectin/vWF binding to ADP- and thrombin-stimulated platelets with structure–activity analysis\",\n      \"pmids\": [\"6326808\", \"6325435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full thermodynamic parameters for peptide–integrin interaction not determined\",\n        \"Three-dimensional structural basis of the γ-chain–αIIbβ3 interface unresolved at this stage\"\n      ]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrating that fibrinogen binds endothelial ICAM-1 to bridge leukocytes to the vessel wall revealed an inflammation-relevant adhesion function of fibrinogen independent of its classical hemostatic integrin interactions.\",\n      \"evidence\": \"Affinity chromatography, direct binding to recombinant ICAM-1, and cell adhesion assays with ICAM-1 transfectants\",\n      \"pmids\": [\"8100742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Gamma-chain residues responsible for ICAM-1 binding not mapped\",\n        \"Contribution of each fibrinogen chain to ICAM-1 recognition not dissected\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Crystal structures of the gamma-chain C-terminal fragment and of fragment D with a bound Gly-Pro-Arg-Pro peptide provided the atomic basis for fibrin polymerization, showing a deep 'hole' pocket in the gamma domain that accepts the complementary 'knob' from adjacent fibrin monomers.\",\n      \"evidence\": \"X-ray crystallography at 2.1–2.9 Å resolution with multiple crystal forms and a synthetic polymerization-site peptide ligand\",\n      \"pmids\": [\"9016719\", \"9333233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full-length hexamer structure not yet available at this point\",\n        \"Dynamics of polymerization pocket opening/closing not captured by static structures\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showing that the S. aureus adhesin FnbpA targets the same gamma-chain C-terminal site recognized by ClfA established that pathogens exploit the platelet-binding determinant of fibrinogen for host cell attachment.\",\n      \"evidence\": \"SPR, fluorescence polarization, and competitive binding assays using recombinant FnbpA domains and gamma-chain peptides in ClfA/ClfB-null S. aureus\",\n      \"pmids\": [\"10788510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Atomic structure of FnbpA–gamma chain complex not solved\",\n        \"Relative in vivo contribution of FnbpA vs. ClfA to fibrinogen-dependent pathogenesis unclear\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Functional studies of the FGG-H2 haplotype (rs2066865) linked a polyadenylation-site SNP to altered γA/γ' chain ratio and DVT risk, providing a molecular mechanism connecting fibrinogen gamma-chain isoform regulation to thrombin's antithrombin-1 activity and thrombotic disease.\",\n      \"evidence\": \"Population case-control study (Leiden Thrombophilia Study) with haplotype-tagging SNPs and fibrinogen γ' quantification\",\n      \"pmids\": [\"16144795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct in vitro demonstration that the SNP alters CstF binding and polyadenylation not yet provided\",\n        \"Replication in diverse populations not reported in this study\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Characterization of FGG loss-of-function mutations—including nonsense, missense, and splice-site variants—established that congenital afibrinogenemia and hypofibrinogenemia arise through at least three distinct pathogenic mechanisms: NMD of truncated transcripts, intracellular retention of assembled but secretion-incompetent hexamers, and aberrant mRNA splicing.\",\n      \"evidence\": \"COS-7/CHO cell transfection, co-expression of mutant and wild-type chains, cycloheximide NMD inhibition, minigene splicing assays, ELISA and immunoblot across multiple mutations\",\n      \"pmids\": [\"15284111\", \"16141000\", \"24011387\", \"20580695\", \"34196169\", \"38233949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for ER retention of specific missense mutants (e.g. W253C) not determined\",\n        \"Genotype–phenotype correlation across mutation classes remains incomplete\",\n        \"NMD efficiency for different PTC positions along FGG not systematically compared\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that cancer cells endogenously synthesize fibrinogen and that FGG knockdown suppresses FGF-2-dependent proliferation—rescued by exogenous fibrinogen—established a non-hemostatic, autocrine growth-promoting role for the gamma chain through direct FGF-2–fibrinogen complex formation.\",\n      \"evidence\": \"RNAi knockdown of FGG in A549/PC-3 cells; thymidine incorporation; co-immunoprecipitation of FGF-2–fibrinogen; FGF-2 binding-deficient mutant control\",\n      \"pmids\": [\"17949478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Gamma-chain residues mediating FGF-2 binding not mapped\",\n        \"In vivo relevance of autocrine fibrinogen in tumor growth not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The full-length human fibrinogen crystal structure at ~3.3 Å completed the atomic picture of the (AαBβγ)₂ hexamer, confirming gamma-chain domain orientation within the D region and revealing αC domain flexibility.\",\n      \"evidence\": \"X-ray crystallography of intact fibrinogen with post-diffraction biochemical validation\",\n      \"pmids\": [\"19296670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"αC domains and γ' C-terminal extension not resolved\",\n        \"No structure of fibrinogen in complex with platelet integrin αIIbβ3\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showing that FGG overexpression promotes hepatocellular carcinoma invasion via Slug/ZEB1-driven EMT extended the cancer-relevant functions of FGG beyond proliferation to invasive behavior through a specific transcription-factor axis.\",\n      \"evidence\": \"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell invasion; Western blot for EMT markers\",\n      \"pmids\": [\"30863175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Upstream receptor or signaling pathway linking extracellular FGG to Slug/ZEB1 induction not identified\",\n        \"Findings limited to a single cell line\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"FGG was shown to drive cholestatic liver fibrosis through dual mechanisms—direct HSC activation and promotion of M2 macrophage polarization—with in vivo validation using targeted siFGG lipid nanoparticles, expanding FGG's pathological roles beyond hemostasis and cancer to fibrotic disease.\",\n      \"evidence\": \"BDL mouse model; LX2/THP-1 co-culture; FGG overexpression and siRNA knockdown in vivo via AEAA-LNP; RNA-seq and macrophage polarization assays\",\n      \"pmids\": [\"42001119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Receptor on HSCs through which FGG signals is not identified\",\n        \"Molecular mechanism linking FGG to M2 macrophage polarization not delineated\",\n        \"Findings from a single lab and model system\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the gamma chain–αIIbβ3 integrin complex, the receptor and signaling pathway by which secreted FGG activates EMT and HSCs, and how oxidative post-translational modifications of fibrinogen modulate clot structure and disease risk.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No co-crystal structure of gamma chain bound to integrin αIIbβ3\",\n        \"No receptor identified for FGG on hepatic stellate cells or cancer cells driving EMT\",\n        \"Functional significance of oxidative PTMs on fibrinogen gamma chain in vivo undetermined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [3, 4, 10]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 5, 9, 10]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [4, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 1, 3, 4, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 7, 12, 17]}\n    ],\n    \"complexes\": [\n      \"Fibrinogen hexamer (AαBβγ)₂\",\n      \"FGF-2–fibrinogen complex\"\n    ],\n    \"partners\": [\n      \"FGA\",\n      \"FGB\",\n      \"ITGA2B\",\n      \"ITGB3\",\n      \"ICAM1\",\n      \"FGF2\",\n      \"F13A1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}